SCHEMBL3109286

SCHEMBL3109286

CCNC(=O)c1ccc(N)c(OCC)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.53
HSD17B10 Q99714 2/20 0.53
NPC1 O15118 1/20 0.53
USP2 O75604 1/20 0.53
RAB9A P51151 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
ALDH1A1 P00352 4/20 0.51
KMT2A Q03164 4/20 0.51
MEN1 O00255 2/20 0.51
MAPK1 P28482 2/20 0.51
KDM4E B2RXH2 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
POLB P06746 1/20 0.51
MAPT P10636 1/20 0.51
HPGD P15428 1/20 0.51
CREBBP Q92793 1/20 0.51
ALOX15 P16050 1/20 0.50
BRD4 O60885 1/20 0.47
LMNA P02545 1/20 0.47
HDAC3 O15379 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14454254 0.88 TP53 (0.58) TP53HSD17B10NPC1USP2RAB9A
SCHEMBL3105206 0.88 MAPT (0.52) TP53RAB9ASMN1; SMN2L3MBTL1MAPT
SCHEMBL2546019 0.86 HTR4 (0.56) TP53NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL13575618 0.86 PLK1 (0.57) TP53HSD17B10NPC1USP2RAB9A
SCHEMBL13753800 0.86 TP53 (0.65) TP53NPC1RAB9ASMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL3112505 0.85 HTR4 (0.55) TP53NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL3114593 0.84 BRD4 (0.69) TP53NPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL13575488 0.84 ALDH1A1 (0.64) TP53HSD17B10NPC1USP2RAB9A
SCHEMBL12125067 0.83 TP53 (0.55) TP53NPC1RAB9AALDH1A1KMT2A
SCHEMBL12533173 0.83 BRD4 (0.49) TP53NPC1RAB9ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 US disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 US disclosed
EP-1867331-A1 TRIAZOLE DERIVATIVE AND THE USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105253-A1 Triazole Derivative and Use Thereof F2R, HRH4, F2RL3 TP53 2716/4885HSD17B10 1406/4885NPC1 2145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.